About Asialoglycoprotein receptor 2
Asialoglycoprotein receptor 2 (ASGR2) is a protein
from Homo sapiens identified by UniProt accession
P07307, 311 residues long.
MolForge cross-references it against 0 known binders and
49 disease associations.
Target properties
| Protein name | Asialoglycoprotein receptor 2 |
| UniProt accession | P07307 |
| Gene | ASGR2 |
| Organism | Homo sapiens |
| Length | 311 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (49)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.34
- alkaline phosphatase measurement · score 0.25
- IGF-1 measurement · score 0.21
- blood protein measurement · score 0.18
- Hypercholesterolemia · score 0.17
- neuroinflammatory disorder · score 0.14
- Red cell distribution width · score 0.13
- interleukin 6 receptor subunit beta measurement · score 0.08
- Immunodeficiency due to a late component of complements deficiency · score 0.07
- sex hormone-binding globulin measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P07307-F1 | alphafold | PREDICTED | 78.73 | — |
Amino-acid sequence (311 residues)
MAKDFQDIQQ LSSEENDHPF HQGEGPGTRR LNPRRGNPFL KGPPPAQPLA QRLCSMVCFS LLALSFNILL LVVICVTGSQ SEGHGGAQLQ AELRSLKEAF SNFSSSTLTE VQAISTHGGS VGDKITSLGA KLEKQQQDLK ADHDALLFHL KHFPVDLRFV ACQMELLHSN GSQRTCCPVN WVEHQGSCYW FSHSGKAWAE AEKYCQLENA HLVVINSWEE QKFIVQHTNP FNTWIGLTDS DGSWKWVDGT DYRHNYKNWA VTQPDNWHGH ELGGSEDCVE VQPDGRWNDD FCLQVYRWVC EKRRNATGEV A
Explore Asialoglycoprotein receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets